The 7 major substance use disorder markets reached a value of USD 5.3 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 7.7 Million by 2035, exhibiting a growth rate (CAGR) of 3.51% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 5.3 Million |
Market Forecast in 2035
|
USD 7.7 Million |
Market Growth Rate 2025-2035
|
3.51% |
The substance use disorder market has been comprehensively analyzed in IMARC's new report titled "Substance Use Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Substance use disorder (SUD) refers to a chronic, relapsing medical condition that is characterized by compulsive drug or alcohol usage. It can have a significant impact on an individual's physical and mental health, relationships, work, and overall quality of life. Substance use disorder can develop through recreational drug use or by prolonged consumption of prescribed medications, such as painkillers. Symptoms of the condition can vary depending on the substance used, the frequency and amount of use, and the individual's medical and personal history. Some of the common symptoms of SUD are strong urges to consume drugs or alcohol, continued substance use despite negative consequences, withdrawal signs like anxiety, agitation, insomnia, physical symptoms like nausea and sweating, etc. Other indications include social, legal, and financial problems, strained relationships with family and friends, etc. Diagnosis of SUD usually involves a thorough evaluation by a healthcare professional, including medical history, physical examination, and behavioral assessment.
The rising usage of prescription/illicit drugs coupled with the increasing consumption of tobacco and alcohol is primarily driving the global substance use disorder market. In addition to this, the emerging popularity of outpatient rehabilitation programs, which allow individuals to live at home while receiving regular treatment, such as therapy or medication-assisted treatment (MAT), is further creating a positive outlook for the market. Moreover, several government bodies across the globe are taking initiatives to create awareness and understanding of SUD as a treatable medical condition, thus reducing the stigma associated with it and encouraging more people to seek treatment. This, in turn, is acting as a significant growth-inducing factor. Apart from this, the introduction of private insurance coverage for substance abuse disorder treatment, which has made it easier for individuals to access and afford the medicament, is also propelling the global market. Additionally, the escalating utilization of holistic therapeutic approaches, such as yoga, meditation, acupuncture, etc., in combination with traditional SUD treatments to address the physical, emotional, and spiritual aspects of substance abuse is further bolstering the market growth. Besides this, the widespread adoption of behavioral therapies, including cognitive-behavioral therapy (CBT) and motivational interviewing, which help in identifying and changing negative thought patterns and behaviors related to substance abuse, is expected to drive the global substance use disorder market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the substance use disorder market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for substance use disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the substance use disorder market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current substance use disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Brixadi (Buprenorphine) | Braeburn |
Vivitrol (Naltrexone) | Alkermes |
Sublocade (Buprenorphine extended-release) | Indivior |
Psilocybin | Revive Therapeutics |
IBX-210 | atai Life Sciences |
INDV-2000 | Indivior |
Mavoglurant (STP7 /AFQ056) | STALICLA/Novartis |
TMP-301 | Tempero Bio |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Substance Use Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies